The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Nitrofurantoin, an antibiotic medication approved in 1953 by Procter & Gamble, is used to treat uncomplicated lower urinary tract infections.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Phase 2 results of IL-27, PD-(L)1, VEGF blockade using casdozokitug, atezo, and bev in uHCC patients were presented at 2024 ASCO_GI on Jan 18th.

Findings on CSL and Arcturus' sa-mRNA technology suggest extended immunity compared to standard mRNA COVID booster shots.

Hydrocodone bitartrate is a drug commonly used for pain relief, approved first in the United States. The drug works by binding to opioid receptors in the brain, acting as a mu/kappa/delta agonist.

Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.

The latest clinical results of ADG-126 for metastatic MSS CRC treatment were shared at the 2024 ASCO_GI on Jan 20, 2024.

MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.

Valacyclovir Hydrochloride, sold under the brand name Valtrex, is an antiviral drug that was first approved in the USA in 1995.

Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.

Dicyclomine Hydrochloride, sold as BENTYL, is an antispasmodic and anticholinergic drug. Introduced in 1950 for Irritable Bowel Syndrome treatment in the US, it has now been removed from the market.